Mutational signatures may single out breast cancer patients most likely to benefit from platinum-based chemo

The presence in advanced breast cancer of mutational signatures characteristic of homologous recombination deficiency (HRD) was associated with improved clinical outcomes to treatment with platinum-based chemotherapy. it was published in Clinical Cancer...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2C8qGX9
via IFTTT